Cytokine-induced killer (CIK) cells are ex vivo-expanded cytotoxic lymphocytes characterized by broad, MHC-unrestricted antitumor activity and a favorable safety profile. This thesis investigated CIK-cell generation, functionality, and different strategies relevant to their potential clinical application. First, the TheraPEAK T-VIVO medium was compared with the standard X-VIVO15 medium. CIK cells expanded similarly under both conditions, showing comparable viability, phenotype, and cytotoxic activity. Since T-VIVO provided no clear functional advantage and is considerably more expensive, these findings do not support replacing X-VIVO15 for routine CIK-cell culture. Second, CIK-cell activity against B-cell lymphoma models was evaluated in the presence of lenalidomide, alone or combined with the anti-CD19 antibody tafasitamab. Under the tested conditions, lenalidomide did not significantly affect CIK-cell cytotoxicity, neither enhancing nor impairing their antitumor activity, suggesting that it is compatible with CIK-based therapeutic combinations. Finally, the feasibility of generating CIK cells from glioblastoma patients was investigated. Patient-derived PBMCs were successfully expanded into functional CIK cells that retained cytotoxic activity against glioblastoma cell lines. In parallel, healthy donor-derived CIK cells were co-cultured with M2-like macrophages to model the immunosuppressive myeloid component of the glioblastoma tumor microenvironment. Unexpectedly, M2-like macrophages did not reduce CIK-cell proliferation and appeared instead to increase it, suggesting a more complex interaction that requires further investigation. Overall, these results confirm the robustness and versatility of CIK cells, support their compatibility with lenalidomide-based treatments, and provide preliminary evidence for their potential application in both hematological malignancies and glioblastoma.

Cytokine-induced killer (CIK) cells are ex vivo-expanded cytotoxic lymphocytes characterized by broad, MHC-unrestricted antitumor activity and a favorable safety profile. This thesis investigated CIK-cell generation, functionality, and different strategies relevant to their potential clinical application. First, the TheraPEAK T-VIVO medium was compared with the standard X-VIVO15 medium. CIK cells expanded similarly under both conditions, showing comparable viability, phenotype, and cytotoxic activity. Since T-VIVO provided no clear functional advantage and is considerably more expensive, these findings do not support replacing X-VIVO15 for routine CIK-cell culture. Second, CIK-cell activity against B-cell lymphoma models was evaluated in the presence of lenalidomide, alone or combined with the anti-CD19 antibody tafasitamab. Under the tested conditions, lenalidomide did not significantly affect CIK-cell cytotoxicity, neither enhancing nor impairing their antitumor activity, suggesting that it is compatible with CIK-based therapeutic combinations. Finally, the feasibility of generating CIK cells from glioblastoma patients was investigated. Patient-derived PBMCs were successfully expanded into functional CIK cells that retained cytotoxic activity against glioblastoma cell lines. In parallel, healthy donor-derived CIK cells were co-cultured with M2-like macrophages to model the immunosuppressive myeloid component of the glioblastoma tumor microenvironment. Unexpectedly, M2-like macrophages did not reduce CIK-cell proliferation and appeared instead to increase it, suggesting a more complex interaction that requires further investigation. Overall, these results confirm the robustness and versatility of CIK cells, support their compatibility with lenalidomide-based treatments, and provide preliminary evidence for their potential application in both hematological malignancies and glioblastoma.

Optimizing Cytokine-Induced Killer Cells as an Adoptive Cell Therapy Platform for Cancer treatment.

BERARDI, TOMMASO
2025/2026

Abstract

Cytokine-induced killer (CIK) cells are ex vivo-expanded cytotoxic lymphocytes characterized by broad, MHC-unrestricted antitumor activity and a favorable safety profile. This thesis investigated CIK-cell generation, functionality, and different strategies relevant to their potential clinical application. First, the TheraPEAK T-VIVO medium was compared with the standard X-VIVO15 medium. CIK cells expanded similarly under both conditions, showing comparable viability, phenotype, and cytotoxic activity. Since T-VIVO provided no clear functional advantage and is considerably more expensive, these findings do not support replacing X-VIVO15 for routine CIK-cell culture. Second, CIK-cell activity against B-cell lymphoma models was evaluated in the presence of lenalidomide, alone or combined with the anti-CD19 antibody tafasitamab. Under the tested conditions, lenalidomide did not significantly affect CIK-cell cytotoxicity, neither enhancing nor impairing their antitumor activity, suggesting that it is compatible with CIK-based therapeutic combinations. Finally, the feasibility of generating CIK cells from glioblastoma patients was investigated. Patient-derived PBMCs were successfully expanded into functional CIK cells that retained cytotoxic activity against glioblastoma cell lines. In parallel, healthy donor-derived CIK cells were co-cultured with M2-like macrophages to model the immunosuppressive myeloid component of the glioblastoma tumor microenvironment. Unexpectedly, M2-like macrophages did not reduce CIK-cell proliferation and appeared instead to increase it, suggesting a more complex interaction that requires further investigation. Overall, these results confirm the robustness and versatility of CIK cells, support their compatibility with lenalidomide-based treatments, and provide preliminary evidence for their potential application in both hematological malignancies and glioblastoma.
2025
Optimizing Cytokine-Induced Killer Cells as an Adoptive Cell Therapy Platform for Cancer treatment.
Cytokine-induced killer (CIK) cells are ex vivo-expanded cytotoxic lymphocytes characterized by broad, MHC-unrestricted antitumor activity and a favorable safety profile. This thesis investigated CIK-cell generation, functionality, and different strategies relevant to their potential clinical application. First, the TheraPEAK T-VIVO medium was compared with the standard X-VIVO15 medium. CIK cells expanded similarly under both conditions, showing comparable viability, phenotype, and cytotoxic activity. Since T-VIVO provided no clear functional advantage and is considerably more expensive, these findings do not support replacing X-VIVO15 for routine CIK-cell culture. Second, CIK-cell activity against B-cell lymphoma models was evaluated in the presence of lenalidomide, alone or combined with the anti-CD19 antibody tafasitamab. Under the tested conditions, lenalidomide did not significantly affect CIK-cell cytotoxicity, neither enhancing nor impairing their antitumor activity, suggesting that it is compatible with CIK-based therapeutic combinations. Finally, the feasibility of generating CIK cells from glioblastoma patients was investigated. Patient-derived PBMCs were successfully expanded into functional CIK cells that retained cytotoxic activity against glioblastoma cell lines. In parallel, healthy donor-derived CIK cells were co-cultured with M2-like macrophages to model the immunosuppressive myeloid component of the glioblastoma tumor microenvironment. Unexpectedly, M2-like macrophages did not reduce CIK-cell proliferation and appeared instead to increase it, suggesting a more complex interaction that requires further investigation. Overall, these results confirm the robustness and versatility of CIK cells, support their compatibility with lenalidomide-based treatments, and provide preliminary evidence for their potential application in both hematological malignancies and glioblastoma.
CIK Cells
ACT
Glioblastoma
Lenalidomide
File in questo prodotto:
File Dimensione Formato  
Berardi_Tommaso.pdf

Accesso riservato

Dimensione 2.06 MB
Formato Adobe PDF
2.06 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/115433